Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | APOB | P04114 | 1/20 | 0.33 |
| ▸ | MTTP | P55157 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.32 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8397010 | 0.91 | EPHX1 (0.45) | EPHX1HRH4HRH3TDP1SIGMAR1 | |
| SCHEMBL4437804 | 0.85 | EPHX1 (0.49) | EPHX1PRMT3TDP1 | |
| SCHEMBL4437802 | 0.85 | EPHX1 (0.49) | EPHX1PRMT3TDP1 | |
| SCHEMBL8391372 | 0.83 | EPHX1 (0.53) | EPHX1HRH4HRH3SIGMAR1NPC1 | |
| SCHEMBL8393398 | 0.83 | EPHX1 (0.49) | EPHX1HRH4HRH3SIGMAR1TPSAB1 | |
| SCHEMBL8391889 | 0.81 | EPHX1 (0.56) | EPHX1HRH4HRH3SIGMAR1NPC1 | |
| SCHEMBL8396101 | 0.81 | EPHX1 (0.56) | EPHX1HRH4HRH3SIGMAR1NPC1 | |
| SCHEMBL23826211 | 0.79 | PRMT3 (0.41) | EPHX1PRMT3SMYD3TDP1NPC1 | |
| SCHEMBL4439406 | 0.79 | PRMT3 (0.41) | EPHX1PRMT3SMYD3TDP1NPC1 | |
| SCHEMBL8396346 | 0.79 | EPHX1 (0.52) | EPHX1HRH4HRH3TDP1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | EPHX1 210/4885PRMT3 557/4885HRH4 114/4885 |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | EPHX1 210/4885PRMT3 557/4885HRH4 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.